Study Utilizing Imaging Mass Cytometry Details Changes in Lung Tissue Architecture at the Single-Cell Level in Patients with COVID-19 - Seite 3
About Imaging Mass Cytometry
Imaging Mass Cytometry is setting a new standard in tissue imaging, significantly simplifying high-multiplex panel design and eliminating the impact of tissue autofluorescence by using highly pure
metal tags for which signals are separated by mass instead of by wavelength. Incorporating an easy-to-use immunohistochemistry workflow that simultaneously detects many proteins in a single scan,
IMC is ideal for uncovering new insights in health and disease and empowering the development of better diagnostics and more effective therapies.
About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics
technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of
more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Imaging Mass Cytometry and IMC are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Lesen Sie auch
Forward-Looking Statements for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the benefits of
Fluidigm technology for research and development of COVID-19 therapies. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ
materially from currently anticipated results, including but not limited to risks relating to company research and development, sales, marketing, and distribution plans and capabilities; reductions
in research and development spending or changes in budget priorities by customers; potential product performance and quality issues; intellectual property risks; and competition. Information on
these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year
ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date
hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.